Navigation Links
Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
Date:1/15/2008

BEVERLY HILLS, Calif., Jan. 15 /PRNewswire/ -- Zetia (ezetimibe) "may not actually prevent heart attacks and strokes," according to the long-awaited results of the Enhance trial. Typically, patients "take Zetia in the form of Vytorin (ezetimibe and simvastatin), which combines Zetia with Zocor (simvastatin)." Zetia and Vytorin are jointly marketed by Merck & Co. and Schering-Plough Corp.

Zetia reduces cholesterol 15 to 20 percent in most patients, no trial has been completed yet that has ever shown that it can reduce heart attacks and strokes -- or even that it reduces the growth of the fatty plaques in arteries that can cause heart problems. The Enhance trial "was designed to show that Zetia could reduce the growth" of fatty plaques in arteries. However, "the plaques actually grew by 0.005 mm more in those taking Zetia along with Zocor than in those taking Zocor alone."

The trial was conducted by a group headed by Dr. John J.P. Kastelein of the University of Amsterdam Medical Center. All 720 participants suffered from an unusual condition known as heterozygous familial hypercholesterolemia. Vytorin cut "LDL levels by 58 percent, compared to a 41 percent reduction with simvastatin alone. However, the researchers found that "the average thickness of the carotid artery plaque increased by 0.0111 of a millimeter in patients taking Vytorin, compared to an increase of 0.0058 of a millimeter in" those taking only simvastatin. According to Dr. Norman Lepor, Westside Medical Associates of Los Angeles and an expert on the treatment of hyperlipidemia, "The complete clinical trial results will be researchers plan to present their data in March at a meeting of the American College of Cardiology." He also said that "one should not confuse the very, very small increase in carotid plaque dimension with a risk of cardiovascular events, as this event data has not yet been presented. Since there do not seem to be any safety issues, there is no urgency to having p
'/>"/>

SOURCE Westside Medical Associates of Los Angeles
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
2. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
3. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
4. Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
5. Health Experts and Families Encourage Annual Childhood Flu Vaccination to Reduce Flu-Related Illnesses and Deaths in Children
6. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
7. Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows
8. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ongoing Phase Ib trial demonstrated a 2.5 log10 me...nference Call Today at 8:30AM EST , , SAN DIEG...euticals, Inc. (Nasdaq: ANDS ) today announced r...b clinical trial of ANA598, the Company,s investig...98 was very well-tolerated and demonstrated potent...
(Date:1/7/2009)...sed On Osteotech,s Proprietary Human Collagen Tech...iling Anticipated in Third Quarter 2009 , , EA...Osteotech, Inc. (Nasdaq: OSTE ), a leader in the...ive healing, announced today that it has initiated...Regeneration Matrix. The first five patients in th...
(Date:1/6/2009)...cent controlled studies conducted by Dr. Richard B...that the patented ingredient in Glyc,n Go(TM), Gly... to increase levels of nitric oxide (NO) in the bo... in human subjects. , , Nitric oxide acts as a ...to the skeletal muscles. This is significant to 1...
(Date:1/6/2009)...rstCall/ -- , - Early Renewal of the Agreem...11 , - Expansion of the Scope of the Collab...ology , - Revised Commercial Terms and Paym...d Party , ExonHit Therapeutics (Alternext...xisting drug discovery collaboration with Allergan...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4NBTY Announces Preliminary Unaudited Net Sales Results For August 2007 610 1NBTY Announces Preliminary Unaudited Net Sales Results For August 2007 610 2NBTY Announces Preliminary Unaudited Net Sales Results For August 2007 610 3The New England Journal of Medicine Publishes EURIDIS ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrill 607 1The New England Journal of Medicine Publishes EURIDIS ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrill 607 2The New England Journal of Medicine Publishes EURIDIS ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrill 607 3The New England Journal of Medicine Publishes EURIDIS ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrill 607 4The New England Journal of Medicine Publishes EURIDIS ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrill 607 5ThermoGenesis Corp to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12 2007 392 1ThermoGenesis Corp to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12 2007 392 2ThermoGenesis Corp to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12 2007 392 3Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 202 1Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 202 2Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 202 3Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 202 4Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 202 5Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 202 6Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 202 7
... to Company Oncology Programs to be Presented, SOU...re-FirstCall/ -- Cytokinetics, Incorporated announ...l data will be,presented at the 2007 Annual Meetin...(AACR) to be held from April 14- 18, 2007 in,Los A...oncology,programs at Cytokinetics and will present...
...a.--(BUSINESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline...:ADLR) today announced data from Study 767905/014 ... program for,alvimopan (Entereg/Entrareg(R))., Stu...d (12,month) study, was designed to evaluate the l...mg twice daily in patients taking,opioids for chro...
Other Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
(Date:1/8/2009)...dications are available that work, CDC officials s...ws) -- The most common strain of flu this season i... but government health officials said Thursday the...lu season so far has been slow, and that other dru...s health officials adopting a watchful attitude fo...
(Date:1/8/2009)...of sugar sitting on the surface of cancer cells ar...t both treating and stopping the spread of certain... prostate, breast, ovarian and lung, among others....m the Gateway for Cancer Research, an Illinois-bas...ra Franco, M.D., Ph.D., and her co-workers at the ...
(Date:1/8/2009)...quick to condemn hurtful comments, study suggests ...- Many people overestimate how strongly they would... , Sixty-three percent of study participants at...er for an experiment with a white person rather th...acist comments about the black person when he left...
(Date:1/8/2009)...AGO, Jan. 8 Allscripts-M...pts Healthcare Solutions, Inc. (Allscripts or,the...or the three and six,months ended November 30, 20...n/prnh/20061005/ALLSCRIPTSLOGO-b ) , The Co... November 30, 2008,include results from legacy Al...
Breaking Medicine News(10 mins):Health News:Common Flu Strain Resistant to Popular Antiviral Drug 2Health News:Common Flu Strain Resistant to Popular Antiviral Drug 3Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Many Turn Blind Eye to Racism 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13
...allowed the counter sale of the diet drug, orlista... possesses a prescription under the name Xenical. ... in the reduction of six pounds in six months time...x pounds in six months. These like any other diet ...
...nal Institute of Immunology are reported to have i...nderstand how the tuberculosis (TB) bacteria survi...oping newer and more effective medicines to combat...ives across the world annually. The research team ...
...Prime Minister Ariel Sharon have declared that his...ive state. // He is also not expected to regain co...orrhage, and he is still breathing with the help o...is reported to be stable. The Re'ut Rehabilitati...
...been granted fast track designation by the US Food...ived the orphan drug designation // recently for t...ally advanced and metastatic medullary thyroid can... drug in the treatment of medullary thyroid carcin...
Other Medicine News:Health News:Demand For Diet Drugs On The Rise 2
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm).
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm).
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm).
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm).
Medicine Products: